Compare Abeona Therapeutics Inc (ABEO) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares MSCI United Kingdom (FTSE) — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while iShares MSCI United Kingdom (FTSE) trades at $46.48. Which is the better fit depends on your goals.
| ABEO | EWU | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $48.68 |
52-Week Low | $4.17 | $39.59 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EWU trades at $47.22, showing slight daily gains with a bullish technical outlook supported by moving averages. The ETF reflects UK market exposure, with recent news highlighting political uncertainty and economic challenges. Technical indicators show mixed signals with RSI suggesting potential overbought conditions near-term.
The outlook remains cautious due to UK political instability and economic headwinds, though potential short-squeeze dynamics and record European equity performances offer upside. Key risks include sterling weakness and domestic policy shifts. Investors should weigh geopolitical factors against valuation discounts in UK assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →
